---
title: "Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285713695.md"
description: "Kiora Pharmaceuticals Inc reported its Q1 2026 results, showing a comprehensive loss of $2.4M and a net loss of $2.42M, with a diluted EPS of $0.58. This reflects a year-over-year increase in losses. The company executed a global license for KIO-301, received $16M upfront, and initiated Phase 2 trials for its pipeline products. R&D expenses are largely reimbursed, with cash runway projected into late 2028."
datetime: "2026-05-08T11:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285713695.md)
  - [en](https://longbridge.com/en/news/285713695.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285713695.md)
---

# Kiora Pharmaceuticals Inc 1Q 2026: Revenue ($2.4M), Net income ($2.42M), EPS ($0.58) — 10-Q Summary

Kiora Pharmaceuticals Inc reported results for the first quarter of fiscal 2026, posting a comprehensive loss of ($2.4M) and a net loss of ($2.42M), or diluted loss per share of ($0.58), compared with losses of ($2.21M), ($2.19M) and ($0.52) respectively in the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($2.4M)

($2.21M)

(8.7%)

Net income²

($2.42M)

($2.19M)

(10.3%)

Diluted EPS³

($0.58)

($0.52)

(11.5%)

_¹ Reported as “Comprehensive Loss”. ² Reported as “Net Loss”. ³ Reported as “Loss per Common Share - Diluted”._

**Business Highlights**

-   Partnership & licensing: Executed an exclusive global license (ex-Asia) for KIO-301 with Théa Open Innovation, including $16M upfront plus potential milestones and royalties.
-   Clinical progress: Completed Phase 1b ABACUS-1 with positive topline and full data; Phase 2 ABACUS-2 initiated in 2025 with dosing underway.
-   Asian expansion option: Granted Senju an exclusive option for key Asian territories for KIO-301 with a $1.25M nonrefundable option fee and up to $109.5M plus royalties if exercised.
-   Pipeline: Advanced KIO-104 into Phase 2 for retinal inflammation; KIO-101 is paused and available for partnership.
-   Funding outlook: R&D expenses for KIO-301 are largely reimbursed by the partner, with cash runway projected into late 2028 to support planned operations.

Original SEC Filing: KIORA PHARMACEUTICALS INC \[ KPRX \] - 10-Q - May. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KPRX.US](https://longbridge.com/en/quote/KPRX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)